Anti-egfr antibody and anti-c-met/anti-egfr bispecific antibodies comprising the same
AssigneeSamsung Electronics Co., Ltd.
InventorsMi Young CHO, Seung Hyun Lee, Kwang Ho Cheong, Young Jun Koh, Jung Wook Lee, Powei Lin, Jae Woong Hwang
Life of this patent
Estimating the term…
Abstract
An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.
Claims19
A polypeptide comprising one amino acid sequence, or a combination of two or more amino acid sequences, selected from the group consisting of SEQ ID NOs:
- 109 to 114.
An anti-EGFR antibody or an antigen-binding fragment thereof, comprising:
- at least one heavy chain complementarity determining region selected from the group consisting of a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 111;
- at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 114;
- or
- a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.
An anti-c-Met/anti-EGFR bispecific antibody comprising an anti-c-Met antibody or an antigen-binding fragment thereof and an anti-EGFR antibody or an antigen-binding fragment thereof, wherein
- the anti-c-Met antibody or an antigen-binding fragment thereof binds to an epitope comprising 5 or more contiguous amino acids of SEQ ID NO:
- 79;
- and
- the anti-EGFR antibody or an antigen-binding fragment thereof comprises:
- at least one heavy chain complementarity determining region selected from the group consisting of a CDR-H1 comprising the amino acid sequence of SEQ ID NO:
- 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO:
- 110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO:
- 111;
- at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO:
- 112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO:
- 113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO:
- 114;
- or
- a combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.
Dependencies are inferred from the claim text.